medigraphic.com
ISSN 1727-897X (Electronic)

2019, Number 6

<< Back Next >>

Medisur 2019; 17 (6)

Small cell lymphocytic lymphoma of eye annexes. Case presentation

Villares ÁI, Fernández ÁJD, García DMA, Pérez CA

Language: Spanish
References: 29
Page: 895-902
PDF size: 258.40 Kb.


ABSTRACT

Lymphomas are malignant diseases that originate in the immune system cells and are predominantly manifested by lymphadenopathy; sometimes the presentation is in extranodal places. The eye and its annexes may be affected by a heterogeneous group of primary lymphomas or, secondarily, by the extension of lymphomas originated in lymph nodes or other extranodal sites. The case of a patient who went to the consultation due to left palpebral ptosis is reported and physical examination showed bilateral involvement, with tumors in the lower right eye bulbar conjunctiva and in the left eye upper bulbar conjunctiva. A small B cell lymphocytic non-Hodgkin lymphoma was diagnosed by conjunctiva biopsy. The patient was considered a stage IIIAE of Ann Arbor and treated with six cycles of cyclophosphamide, vincristine, doxorubicin and prednisone, plus the Cuban monoclonal antibody anti-CD20 CIMABior®. The complete response was reached, state in which the disease remains so far.


REFERENCES

  1. Al-Naeeb AB, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.

  2. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310.

  3. Alcocer-Gamba MA, León-González S, Castro-Montes E, Loarca-Piña LM. Atypical presentation of diffuse large B-cell non-Hodgkin lymphoma. Rev Med Inst Mex Seguro Soc [revista en Internet]. 2015 [citado 05/05/2019];53(2):[aprox. 7p]. Disponible en: Disponible en: http://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=56577.

  4. Kirkegaard MM, Coupland SE, Prause JU, Heegaard S. Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 2015;60(5):444-58.

  5. Gómez-BauteI R, González-Yglesias Y, Dita-SalabertI LM, Fernández-Águila JD, Espinosa-Martínez E, Arencibia-Núñez A. Tumor de la órbita como forma poco común de presentación de un linfoma no hodgkiniano extranodal de la zona marginal. Rev Cubana Hematol Inmunol Hemoter. 2010;26(1):76-82.

  6. Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: aclinicopathologic study of a rare disease. Am J Med Sci. 2006;331(2):79-83.

  7. Roque MR, Law SK, Roy H, Phillpotts BA, Menon-Mehta S. Ocular Lymphoma: Overview, Pathophysiology, Epidemiology [Internet]. Silicon Alley: Medscape; 2016 [citado 10/06/2019]. Disponible en: Disponible en: https://emedicine.medscape.com/article/1219134-overview.

  8. Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int. 2015 ; 2015: 895105.

  9. Iqbal M, Castano YG, Sher T, Kharfan-Dabaja MA. Intraocular involvement of mantle cell lymphoma: a case report and literature review. Hematol Oncol Stem Cell Ther. 2019;S1658-3876(19):30027-5.

  10. Ponzoni M, Govi S, Licata G, Mappa S, Giordano Resti A. A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma. Oncologist. 2013;18(7):876-84.

  11. Munch Petersen HD, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. JAMA Ophthalmol. 2015;133(2):165-73.

  12. Verdijk RM. Lymphoproliferative tumors of the ocular adnexa. Asia Pac J Ophthalmol (Phila). 2017 ; 6 (2): 132-42..

  13. Neudorfer M, Kessler A, Anteby I, Goldenberg D, Barak A. Co-existence of intraocular and orbital lymphoma. Acta Ophthalmol Scand. 2004;82(6):754-61.

  14. Jeon YW, Yang HJ, Choi BO, Jung SE, Park KS, Joo Hyun O, et al. Comparison of selection and long-term clinical outcomes between chemotherapy and radiotherapy as primary therapeutic modality for ocular adnexal MALT lymphoma. EClinical Medicine [revista en Internet]. 2018 [citado 10/06/2019];4(5):[aprox. 11p]. Disponible en: Disponible en: https://www.thelancet.com/action/showPdf?pii=S2589-5370(18)30033-6.

  15. Kalogeropoulos D, Papoudou-Bai A, Kanavaros P, Kalogeropoulos C. Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue. Clin Exp Med. 2018;18(2):151-63.

  16. Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexa lymphoma: Final results of an international phase II trial. J Clin Oncol. 2012;30:2988-94.

  17. Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. Radiology. 2010;2(2):565-74.

  18. Rojas Bilbao EA, Nesprias M, Pulero C, Giménez L. Linfomas de la órbita y anexos oculares. Correlación clínico patológica de 25 casos. MEDICINA [revista en Internet]. 2010 [citado 10/06/2019];70(4):[aprox. 6p]. Disponible en: Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000400006.

  19. Said J. The expanding spectrum of EBV + lymphomas. Blood. 2015;126(7):827-8.

  20. Gracia E, Froesch P, Mazzucchelli L, Martin V, Rodríguez-Abreu D, Jiménez J, et al. Low prevalence of Chlamydia psittaci inocular adnexal lymphomas from Cuban patients. Leuk Lymphoma. 2007;48(1):104-8.

  21. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586-94.

  22. Miyairi I, Byrne GI. Chlamydia and programmed cell death. Curr Opin Microbiol. 2006;9(1):102-8.

  23. Rosado MF, Byrne GE, Ding F, Fields KA, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood . 2006;107(2):467-72.

  24. Masuda Y, Takeuchi K, Kodama T, Fujisaki T, Imaizumi Y, Otsuka E, et al. Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis. Int J Clin Oncol. 2019; . doi:10.1007/s10147-019-01481-3.

  25. Hindsø TG, Esmaeli B, Holm F, Mikkelsen LH, Rasmussen PK, Coupland SE, et al. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma. Br J Ophthalmol. 2019 Jun 8; . doi:10.1136/bjophthalmol-2019-314008.

  26. Tuncer S, Tanyıldız B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Current Eye Research. 2015;40(8):780-5.

  27. Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int. 2015;2015:895105.

  28. Fernández-Águila JD, García-Vega YA, Hernández-Casaña P, Hernández-Cruz C, Medina-Rodríguez BA, Viada-González CE. Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior®. Rev Cubana Hemat, Inmun y Hemoter [revista en Internet]. 2017 [citado 10/06/2019]; 33 (4):[aprox. 6p]. Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/604/534.

  29. Hernández C, Saumell Y, Fernández JD, Cepero K, Marín D, de la Torre AV, Alcalde M, et al. Safety and preliminary effect of the anti-CD20 monoclonal antibody 1B8 in B cell non-Hodgkin’s lymphoma: results of an Expanded Access Program IJPPR. Human J. 2019;14(4):1-17.




2020     |     www.medigraphic.com